KTE-X19 for Relapsed or Refractory Mantle Cell Lymphoma: ZUMA-2 Trial

In a phase II trial reported in The New England Journal of MedicineMichael Wang, MD, and colleagues found that the anti-CD19...


ASCO Coronavirus Resources

As the coronavirus (COVID-19) continues to spread, organizations all over the world are focusing on the health and safety of their...

Gynecologic Cancers

Does Breastfeeding Affect Invasive Ovarian Cancer Risk?

In a large pooled analysis reported in JAMA Oncology by Babic et al, breastfeeding was associated with a significant reduction...

Multiple Myeloma

Daratumumab for Relapsed or Refractory Multiple Myeloma: Subcutaneous vs Intravenous Dosing

Findings from the phase III COLUMBA trial have shown that subcutaneous daratumumab is not inferior to intravenous daratumumab...


Methylation Signatures From Sequencing Circulating Cell-Free DNA Detected Different Types of Cancer Across Multiple Stages

Researchers have developed the first blood test that can accurately detect more than 50 types of cancer and identify in which tissue the cancer originated...


Sponsored Content

Kidney Cancer

Toni K. Choueiri, MD, on COSMIC-313: Cabozantinib in Combination With Nivolumab/Ipilimumab in RCC

Symptom Management

Treatment With Checkpoint Inhibitors May Cause Thyroid Dysfunction

Thyroid dysfunction following treatment with immune checkpoint inhibitors is more common than previously thought, according to research that was accepted for presentation at ENDO 2020, the Endocrine Society’s annual meeting (Abstract SAT-418), and that will be published in Journal of the Endocrine...


Impact of Genes on Total Number and Type of Nevi

A study by Duffy et al in the Journal of Investigative Dermatology reported on specific gene variations affecting the number and types of moles on the body and their role in causing skin cancer.  “The goal was to investigate the genetic underpinnings of different mole classes, or...

Head and Neck Cancer
Issues in Oncology

Jill Gilbert, MD, on HPV-Associated Oropharyngeal Cancer: Challenges in De-intensifying Systemic Therapies

Gastroesophageal Cancer

Bemarituzumab for FGFR2b-Overexpressing Gastroesophageal Adenocarcinoma

In a phase I trial reported in the Journal of Clinical Oncology, Daniel V.T. Catenacci, MD, PhD, and colleagues found that the first-in-class anti–fibroblast growth factor receptor 2b (FGFR2b) antibody bemarituzumab showed activity in patients with high FGFR2b-overexpressing, advanced-stage...

Breast Cancer

Indigenous American Ancestry May Be Associated With HER2-Positive Breast Cancer

An increased proportion of indigenous American ancestry was associated with a greater incidence of HER2-positive breast cancer, according to a study published in Cancer Research.1 “The risk of breast cancer–related mortality varies between different populations, with Latina women having a greater...

Gemcitabine/Eribulin in Cisplatin-Ineligible Metastatic Urothelial Carcinoma

In the final analysis from a phase II California Cancer Consortium trial (NCI-9653) reported in the Journal of Clinical Oncology, Sadeghi et al found the combination of gemcitabine and eribulin showed activity in cisplatin-ineligible patients with metastatic urothelial carcinoma. Study Details...

Symptom Management
Skin Cancer

Kevin Tyan on Colitis Induced by Immune Checkpoint Inhibitors: Potential Preventive Strategy

Issues in Oncology

Factors Associated With Early Readmissions to Hospital Oncology Services

In a study reported in JCO Oncology Practice, Zibelli et al found that patients with cancer readmitted to hospital within 30 days from index admission often made the decision to return to hospital themselves, without input from their care teams. Study Details The study included 33 patients...


Deintensified Chemoradiotherapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma

In a phase II trial reported in the Journal of Clinical Oncology, Chera et al found that deintensified chemoradiotherapy produced favorable outcomes in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma. Study Details In the multicenter trial, 114 patients were recruited...